Eisai Corporation of North America announced today that the U.S. FDA approved BANZEL (rufinamide) for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. One of the most severe forms of childhood epilepsy, LGS is characterized by multiple and frequent seizures.
The details can be read here.
No comments:
Post a Comment